ATE369860T1 - Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie - Google Patents

Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie

Info

Publication number
ATE369860T1
ATE369860T1 AT01921298T AT01921298T ATE369860T1 AT E369860 T1 ATE369860 T1 AT E369860T1 AT 01921298 T AT01921298 T AT 01921298T AT 01921298 T AT01921298 T AT 01921298T AT E369860 T1 ATE369860 T1 AT E369860T1
Authority
AT
Austria
Prior art keywords
sub
treatment
tyrosine kinase
receptor tyrosine
diabetic nephropathy
Prior art date
Application number
AT01921298T
Other languages
German (de)
English (en)
Inventor
Robert Atkins
Steven Chadban
Mark Cooper
Richard Gilbert
Prudence Hill
Darren Kelly
David Nikolic-Paterson
Original Assignee
Univ Melbourne
Robert Atkins
Chadban Steven James
Cooper Mark Emmanuel
Gilbert Richard Ernest
Hill Prudence Ann
Kelly Darren James
Nikolic Paterson David John
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Melbourne, Robert Atkins, Chadban Steven James, Cooper Mark Emmanuel, Gilbert Richard Ernest, Hill Prudence Ann, Kelly Darren James, Nikolic Paterson David John, Novartis Pharma Gmbh filed Critical Univ Melbourne
Application granted granted Critical
Publication of ATE369860T1 publication Critical patent/ATE369860T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01921298T 2000-03-03 2001-03-01 Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie ATE369860T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00810181 2000-03-03

Publications (1)

Publication Number Publication Date
ATE369860T1 true ATE369860T1 (de) 2007-09-15

Family

ID=8174580

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01921298T ATE369860T1 (de) 2000-03-03 2001-03-01 Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie

Country Status (10)

Country Link
US (1) US7087608B2 (enExample)
EP (1) EP1259242B1 (enExample)
JP (1) JP2003525240A (enExample)
AT (1) ATE369860T1 (enExample)
AU (2) AU4832401A (enExample)
CA (1) CA2401812C (enExample)
DE (1) DE60129934T2 (enExample)
ES (1) ES2291306T3 (enExample)
PT (1) PT1259242E (enExample)
WO (1) WO2001064200A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878697B2 (en) 2001-06-21 2005-04-12 Ariad Pharmaceuticals, Inc. Phenylamino-pyrimidines and uses thereof
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
WO2003004007A2 (en) 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
DK1401413T3 (da) 2001-06-29 2007-03-26 Ab Science Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
EP1401415B1 (en) 2001-06-29 2006-06-21 AB Science Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
IL160310A0 (en) * 2001-08-25 2004-07-25 Arakis Ltd The use of anthroquinones in the treatment of kidney disease
US7332330B2 (en) * 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
EP1469810A4 (en) * 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
CA2490989A1 (en) * 2002-05-13 2003-11-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
EP1525200B1 (en) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
EP1631291B1 (en) * 2003-05-27 2009-08-12 Robert P. Hägerkvist Use of tyrosine kinase inhibitors to treat diabetes
CA2535242A1 (en) * 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
KR20120008093A (ko) 2003-11-17 2012-01-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2602735B2 (ja) * 1989-09-27 1997-04-23 株式会社大塚製薬工場 抗活性酸素剤
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5721277A (en) 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
CA2214393A1 (en) 1996-09-02 1998-03-02 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JPH10182644A (ja) * 1996-11-01 1998-07-07 Takeda Chem Ind Ltd 三環性化合物、その製造法及び剤
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
PT1105136E (pt) 1998-08-13 2007-12-03 Novartis Ag Método para tratar doenças oculares neovasculares

Also Published As

Publication number Publication date
DE60129934T2 (de) 2008-05-08
CA2401812C (en) 2009-06-09
WO2001064200A2 (en) 2001-09-07
HK1052864A1 (en) 2003-10-03
JP2003525240A (ja) 2003-08-26
DE60129934D1 (de) 2007-09-27
US20030186977A1 (en) 2003-10-02
AU2001248324B2 (en) 2005-09-15
EP1259242A2 (en) 2002-11-27
ES2291306T3 (es) 2008-03-01
WO2001064200A3 (en) 2002-01-17
US7087608B2 (en) 2006-08-08
PT1259242E (pt) 2007-11-15
EP1259242B1 (en) 2007-08-15
CA2401812A1 (en) 2001-09-07
AU4832401A (en) 2001-09-12

Similar Documents

Publication Publication Date Title
DE60129934D1 (de) Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie
YU84603A (sh) Novi inhibitori tirozin kinaze
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE281451T1 (de) Imidazolderivate und deren verwendung als raf kinase inhibitoren
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
TR200103352T2 (tr) Kinas pirolotriazin inhibitörleri
DE602004024880D1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
ATE266623T1 (de) Caspase inhibitoren und deren verwendung
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
ATE432259T1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
DK1109785T3 (da) Indolderivater og deres anvendelse til behandling af ondartede og andre sygdomme forårsaget af patologisk celleproliferation
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
DE602005005167D1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
NO963706L (no) Benzenkondenserte heterosykliske derivater og deres anvendelse
BRPI0407841A (pt) inibidores heterocìclicos de quinase
DK1765816T3 (da) Substituerede 1-propinylpiperaziner med affinitet for MGluR5-receptoren til behandling af smertetilstande
ATE360015T1 (de) Protein tyrosin kinase inhibitoren
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60207104D1 (de) 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase
ATE518538T1 (de) Verwendung von substituierten piperazin- und morpholinderivaten
ATE380810T1 (de) Protein-tyrosine-kinase-inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259242

Country of ref document: EP